Janssen Research and Development, L.L.C., a member of Johnson and Johnson's Family of Companies, is seeking a Leader of the World Without Multiple Myeloma initiative, to be located in Spring House, PA or Raritan, NJ.
Dr. Bill Hait, Global Head, Research & Development @ Janssen believes our goal should be a “World Without Disease” by 2030. Read More about this initiative here: http://www.janssen.com/world-without-disease
Janssen Research & Development, LLC
At the Janssen Pharmaceutical Companies of Johnson & Johnson, what matters most is helping people live full and healthy lives. We focus on treating, curing and preventing some of the most devastating and complex diseases of our time. And we pursue the most promising science, wherever it might be found.
We discover and develop innovative medical solutions to address important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.
We are Janssen. Our mission drives us. Our patients inspire us. We collaborate with the world for the health of everyone in it. Bring your talents to our mission, visit http://www.janssenrnd.com/ to learn more.
Thriving on a diverse company culture, celebrating the uniqueness of our employees and committed to inclusion. Proud to be an equal opportunity employer.
Janssen's Oncology Therapeutic Area is committed to a singular vision: to transform cancer to a preventable, chronic or curable disease by delivering extraordinary and accessible diagnostic and therapeutic solutions that prolong and improve patients' lives.
Janssen is developing transformational therapies for multiple myeloma including Velcade and Darzalex that are changing the lives of patients with multiple myeloma. Looking to the future, Janssen is putting the most compelling science to work with an aim to cure multiple myeloma or prevent its progression from earlier precursor stages.
The World Without Multiple Myeloma Leader will design the strategy, and lead the operational execution in delivery of a portfolio of programs with the goal to cure multiple myeloma.
This leader will guide a holistic approach inclusive of discovery and early development of New Molecular Entities, novel target identification, translational research and pioneering continuous innovation in approaches towards curing MM.
Playing a key leadership role in the Hematologic Malignancy Disease Area at a strategic level, you will represent Janssen within the global MM community.
Innovator| Pioneer | Change Agent | Influencer |